Lufironil

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 584560

CAS#: 128075-79-6

Description: Lufironil inhibits CCl4-induced liver fibrosis in rats and inhibits proline hydroxylase.

Chemical Structure

img
Lufironil
CAS# 128075-79-6
Instruction

Theoretical Analysis

MedKoo Cat#: 584560
Name: Lufironil
CAS#: 128075-79-6
Chemical Formula: C13H19N3O4
Exact Mass: 281.14
Molecular Weight: 281.312
Elemental Analysis: C, 55.51; H, 6.81; N, 14.94; O, 22.75

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Lufironil; HOE 077; Lufironilo; Lufironilum

IUPAC/Chemical Name: N,N'-Bis(2-methoxyethyl)-2,4-pyridinedicarboxamide

InChi Key: JUCNGMPTCXPMNB-UHFFFAOYSA-N

InChi Code: InChI=1S/C13H19N3O4/c1-19-7-5-15-12(17)10-3-4-14-11(9-10)13(18)16-6-8-20-2/h3-4,9H,5-8H2,1-2H3,(H,15,17)(H,16,18)

SMILES Code: O=C(C1=NC=CC(C(NCCOC)=O)=C1)NCCOC

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.03.00

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 281.31 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Baader E, Bickel M, Damm D, Donaubauer HH, Fehlhaber HW, Grötsch H, Günzler V, Teetz V, Volz M. Interference in clinical laboratory tests, with special regard to the bilirubin assay: effects of a metabolite of the new prolyl 4-hydroxylase inhibitor, Lufironil. Eur J Clin Chem Clin Biochem. 1994 Jul;32(7):515-20. PubMed PMID: 7981331.

2: Okita K, Sakaida I, Hino K. Current strategies for chemoprevention of hepatocellular carcinoma. Oncology. 2002;62 Suppl 1:24-8. Review. PubMed PMID: 11868781.

3: Horn W. General pharmacology, toxicology and future clinical development of HOE 077. J Hepatol. 1991;13 Suppl 3:S63-5. Review. PubMed PMID: 1667670.

4: Wang YJ, Wang SS, Bickel M, Guenzler V, Gerl M, Bissell DM. Two novel antifibrotics, HOE 077 and Safironil, modulate stellate cell activation in rat liver injury: differential effects in males and females. Am J Pathol. 1998 Jan;152(1):279-87. PubMed PMID: 9422545; PubMed Central PMCID: PMC1858123.

5: Zhang WJ, Marx SK, Laue C, Hyder A, Juergensen A, Bickel M, Schrezenmeir J. HOE 077 reduces fibrotic overgrowth around the barium alginate microcapsules. Transplant Proc. 2000 Feb;32(1):206-9. PubMed PMID: 10701026.

6: Sakaida I, Uchida K, Hironaka K, Okita K. Prolyl 4-hydroxylase inhibitor (HOE 077) prevents TIMP-1 gene expression in rat liver fibrosis. J Gastroenterol. 1999 Jun;34(3):376-7. PubMed PMID: 10433015.

7: Bickel M, Baader E, Brocks DG, Engelbart K, Günzler V, Schmidts HL, Vogel GH. Beneficial effects of inhibitors of prolyl 4-hydroxylase in CCl4-induced fibrosis of the liver in rats. J Hepatol. 1991;13 Suppl 3:S26-33; discussion S34. PubMed PMID: 1667666.

8: Böker K, Schwarting G, Kaule G, Günzler V, Schmidt E. Fibrosis of the liver in rats induced by bile duct ligation. Effects of inhibition by prolyl 4-hydroxylase. J Hepatol. 1991;13 Suppl 3:S35-40. PubMed PMID: 1667667.

9: Böker K, Schwarting G, Kaule G, Günzler V, Ohlendorf S, Schmidt E. [Experimental studies of the inhibition of fibrogenesis]. Z Gastroenterol. 1992 Mar;30 Suppl 1:43-5. German. PubMed PMID: 1333142.

10: Clément B, Chesné C, Satie AP, Guillouzo A. Effects of the prolyl 4-hydroxylase proinhibitor HOE 077 on human and rat hepatocytes in primary culture. J Hepatol. 1991;13 Suppl 3:S41-7. PubMed PMID: 1667668.

11: Matsumura Y, Sakaida I, Uchida K, Kimura T, Ishihara T, Okita K. Prolyl 4-hydroxylase inhibitor (HOE 077) inhibits pig serum-induced rat liver fibrosis by preventing stellate cell activation. J Hepatol. 1997 Jul;27(1):185-92. PubMed PMID: 9252094.

12: Weidenbach H, Lerch MM, Turi S, Bachem M, Adler G. Failure of a prolyl 4-hydroxylase inhibitor to alter extracellular matrix deposition during experimental pancreatitis. Digestion. 1997;58(1):50-7. PubMed PMID: 9018010.

13: Sakaida I, Kubota M, Kayano K, Takenaka K, Mori K, Okita K. Prevention of fibrosis reduces enzyme-altered lesions in the rat liver. Carcinogenesis. 1994 Oct;15(10):2201-6. PubMed PMID: 7955054.

14: Kellner HM, Volz M, Badder E, Kürzel GU, Eckert HG. Pharmacokinetics and metabolism of HOE 077. Preclinical studies. J Hepatol. 1991;13 Suppl 3:S48-61; discussion S62. PubMed PMID: 1667669.

15: Sakaida I, Okita K. New prolyl 4-hydroxylase inhibitor reduces procollagen gene expression and enzyme-altered lesions in rat liver cirrhosis. J Gastroenterol Hepatol. 1995;10 Suppl 1:S63-4. PubMed PMID: 8589346.

16: Sakaida I, Matsumura Y, Kubota M, Kayano K, Takenaka K, Okita K. The prolyl 4-hydroxylase inhibitor HOE 077 prevents activation of Ito cells, reducing procollagen gene expression in rat liver fibrosis induced by choline-deficient L-amino acid-defined diet. Hepatology. 1996 Apr;23(4):755-63. PubMed PMID: 8666329.